Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Current Assets over the past 9 years, most recently at $1.0 billion for Q4 2025.

  • For Q4 2025, Current Assets fell 23.78% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 23.78%, while the annual FY2025 figure was $1.0 billion, 23.78% down from the prior year.
  • Current Assets for Q4 2025 was $1.0 billion at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over five years, Current Assets peaked at $1.4 billion in Q4 2024 and troughed at $157.8 million in Q1 2021.
  • A 5-year average of $642.4 million and a median of $495.2 million in 2022 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: tumbled 31.58% in 2023 and later skyrocketed 207.14% in 2024.
  • Year by year, Current Assets stood at $344.7 million in 2021, then rose by 0.13% to $345.2 million in 2022, then surged by 66.33% to $574.2 million in 2023, then surged by 139.55% to $1.4 billion in 2024, then dropped by 23.78% to $1.0 billion in 2025.
  • Business Quant data shows Current Assets for CRNX at $1.0 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.